SCHEMBL14827232

SCHEMBL14827232

Cc1coc(-c2ccccc2)cc1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.46
TP53 P04637 5/20 0.46
MAPT P10636 5/20 0.46
HPGD P15428 5/20 0.46
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 4/20 0.46
HSD17B10 Q99714 4/20 0.46
SMN1; SMN2 Q16637 4/20 0.45
ABCB1 P08183 4/20 0.44
CYP1B1 Q16678 4/20 0.44
AR P10275 4/20 0.44
TNKS O95271 3/20 0.44
CYP19A1 P11511 3/20 0.44
ABCG2 Q9UNQ0 3/20 0.44
PARP1 P09874 2/20 0.44
TNKS2 Q9H2K2 2/20 0.44
GABRP O00591 1/20 0.44
GABRD O14764 1/20 0.44
NPC1 O15118 1/20 0.44
CA12 O43570 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2432882 0.77 IDH1 (0.53) CYP3A4TP53MAPTHPGDKDM4E
SCHEMBL2432148 0.77 ALDH1A1 (0.55) CYP3A4TP53MAPTHPGDKDM4E
SCHEMBL15316365 0.75 MAOB (0.44) CYP3A4TP53MAPTHPGDKDM4E
SCHEMBL3409831 0.72 MAOB (0.52) MAPTHPGDKDM4EALDH1A1HSD17B10
SCHEMBL674221 0.70 CHRM2 (0.50) CYP3A4TP53HPGDALDH1A1HSD17B10
SCHEMBL1309569 0.69 CYP3A4 (0.46) CYP3A4TP53MAPTHPGDKDM4E
SCHEMBL3972917 0.68 NR4A2 (0.64) TP53MAPTHPGDKDM4EALDH1A1
SCHEMBL9138573 0.68 CYP3A4 (0.67) CYP3A4TP53MAPTHPGDKDM4E
SCHEMBL31303695 0.68 CYP3A4 (0.67) CYP3A4TP53MAPTHPGDKDM4E
SCHEMBL4649417 0.67 CYP1B1 (0.63) CYP3A4TP53MAPTHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9399651-B2 Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders Merck, Sharp & Dohme Corp. (US) 2016-07-26 US disclosed
US-20150299227-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME CORP. (US) 2015-10-22 US disclosed
US-9024032-B2 Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders MERCK SHARP & DOHME CORP. (US) 2015-05-05 US disclosed
US-20130084346-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME LLC 2013-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299227-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS COMT, PNMT, TPMT CYP3A4 124/4885TP53 3443/4885MAPT 220/4885
US-20130084346-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS COMT, PNMT, TPMT CYP3A4 124/4885TP53 3443/4885MAPT 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.